Skip to content
Engineering, Medical Health Aged Care

Researchers “bioprint” living brain cell networks in the lab

Monash University 2 mins read

Monash University Engineering researchers have successfully used “bioinks” containing living nerve cells (neurons) to print 3D nerve networks that can grow in the laboratory and transmit and respond to nerve signals.


Using a tissue engineering approach, and bioprinting with two bioinks containing living cells and non-cell materials respectively, the researchers were able to mimic the arrangement of grey matter and white matter seen in the brain.


Professor John Forsythe of the Department of Materials Science and Engineering, who is leading the research, said while two-dimensional nerve cell cultures have previously been used to study the formation of nerve networks and disease mechanisms, those relatively flat structures don’t reflect the way neurons grow and interact with their surroundings.


“The networks grown in this research closely replicated the 3D nature of circuits in a living brain, where nerve cells extend processes called neurites to form connections between different layers of the cortex,” said Professor Forsythe.


“We found that the projections growing from neurons in the printed ‘grey matter’ or cellular layer readily grew through the ‘white matter’ layer and used it as a ‘highway’ to communicate with neurons in other layers.


“Not only were we able to construct a basic layout similar to what we see in regions of the brain, we found that the neurons actually behaved and performed in a similar manner.”


Sensitive electrophysiological measurements confirmed spontaneous nerve-like activity taking place in the 3D neuronal networks in addition to responses evoked by electrical and drug stimulation.


The presence of detectable electrical activity in tissue engineered 3D networks represents a significant step forward in the field of neuroscience and bioprinting.


Bioprinted 3D neural networks are likely to be a promising platform for studying how nerves and nerve networks form and grow, investigating how some diseases affect neurotransmission, and screening drugs for their effects on nerve cells and the nervous system.


The study, entitled ‘3D Functional Neuronal Networks in Free-Standing Bioprinted Hydrogel Constructs’, is published in
Advanced Healthcare Materials https://doi.org/10.1002/adhm.202300801


For media enquiries please contact:


Loretta Wylde

Monash University Media and Communication

E: loretta.wylde@monash.edu

T: +61 (0) 432 123 106


For more Monash media stories, visit our
news and events site


For general media enquiries please contact:

Monash Media

E: media@monash.edu

T: +61 (0) 3 9903 4840

More from this category

  • Environment, Medical Health Aged Care
  • 01/12/2023
  • 10:43
West Australian doctors peak bodies

WA doctors and health professionals call for the government to take urgent action on climate change and end fossil fuel expansion to protect health

On the 1st December, just prior to the COP28 Health Day on the 3rd December, representatives of the medical colleges for general practitioners (GPs), emergency doctors, rural and remote doctors, and surgeons, as well as other doctors and health professionals, gather at 8 am on the steps of Parliament House to call on the WA Government take urgent action on climate change and protect the health of Western Australians. Reiterating calls from medical colleges earlier this year in support of ending fossil fuel expansion and climate action, those gathered today ask the WA government to: End expansion of any new…

  • Medical Health Aged Care
  • 01/12/2023
  • 10:12
Australian Dental Industry Association

ADIA congratulates Senators of the Inquiry into the Provision of and Access to Dental Services in Australia

1 December The Australian Dental Industry Association congratulates the Senators of the Senate Select Committee Inquiry into the Provision of and Access to Dental…

  • Contains:
  • Medical Health Aged Care, Research Development
  • 01/12/2023
  • 09:17
Aegros

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune Aegros, an Australian clinical-stage biopharmaceutical company leader in the development and manufacture of plasma derived medicinal products (PDMPs), today announced positive top-line interim results from its CHAT clinical trial. Top-line interim results indicate that Aegros’ COVID-19 hyperimmune provides higher levels of antibodies compared to high-titer convalescent plasma. These results are in line with Aegros’ pre-clinical expectations. CHAT compared Aegros’ COVID-19 hyperimmune to COVID-19 convalescent plasma. The hyperimmune was manufactured using Aegros’ patented Haemafrac® process. A hyperimmune is an intravenous immunoglobulin rich in antibodies that can provide passive immunity for…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.